<?xml version="1.0" encoding="UTF-8"?>
<ref id="hep41480-bib-0048">
 <label>48</label>
 <mixed-citation publication-type="journal" id="hep41480-cit-0048">
  <string-name>
   <surname>Heyward</surname>
   <given-names>WL</given-names>
  </string-name>, 
  <string-name>
   <surname>Kyle</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Blumenau</surname>
   <given-names>J</given-names>
  </string-name>, 
  <string-name>
   <surname>Davis</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Reisinger</surname>
   <given-names>K</given-names>
  </string-name>, 
  <string-name>
   <surname>Kabongo</surname>
   <given-names>ML</given-names>
  </string-name>, et al. 
  <article-title>Immunogenicity and safety of an investigational hepatitis B vaccine with a toll‐like receptor 9 agonist adjuvant (HBsAg‐1018) compared to a licensed hepatitis B vaccine in healthy adults 40‐70 years of age</article-title>. 
  <source xml:lang="en">Vaccine</source>
  <year>2013</year>;
  <volume>31</volume>:
  <fpage>5300</fpage>‐
  <lpage>5305</lpage>.
  <pub-id pub-id-type="pmid">23727002</pub-id>
 </mixed-citation>
</ref>
